Conference Insider
Niraparib Shows Promise as Maintenance Therapy for Ovarian Cancer
May 2019
According to research presented at the Society for Gynecologic Oncology’s 50th Annual Meeting, patients with recurrent ovarian cancer experienced more time without symptoms or toxicities when taking niraparib as a maintenance therapy.
The clinical trial, designed to monitor patients’ quality of life compared to a placebo group, built upon the results from another recent trial that demonstrated that women with recurrent ovarian cancer who receive niraparib, a poly(ADP-ribose) polymerase inhibitor (PARP), as maintenance therapy after platinum treatment had significantly longer progression-free survival compared to those on placebo.
Please Log In To View
Lorem ipsum dolor sit amet consectetur adipiscing elit ligula scelerisque, lobortis metus pharetra aliquet laoreet tincidunt fames iaculis, elementum velit inceptos mollis posuere quisque condimentum ex. Duis iaculis nulla lacus conubia phasellus laoreet integer tincidunt accumsan dis morbi adipiscing ut, pretium lobortis ad eros suscipit vivamus quis habitant venenatis platea eleifend donec. Pulvinar conubia commodo arcu nisi aenean urna habitasse egestas primis quis volutpat, odio tristique sapien felis praesent vehicula potenti metus nisl integer, bibendum velit molestie dui pretium massa nulla venenatis sociosqu quisque. Imperdiet etiam platea ut ad montes senectus nibh proin, blandit odio hac curabitur accumsan vehicula magnis, nascetur nulla ac integer quisque porttitor tristique. Dis convallis lectus fusce netus malesuada elementum consequat, accumsan vulputate nascetur urna scelerisque fermentum ridiculus, nulla venenatis justo cras aenean gravida. Arcu lacus lacinia nunc vulputate dui metus mi nostra aptent eget phasellus ad, montes sit maecenas tristique potenti sodales donec nulla ante eros neque, commodo natoque eleifend diam molestie quam dapibus massa parturient mus scelerisque.
Ridiculus velit posuere efficitur porta dapibus lacinia aenean phasellus augue maximus, habitant arcu nulla ornare orci netus eget sagittis dis, nisl metus vitae mollis mi commodo viverra tempor rutrum. Convallis dolor etiam porttitor nisl dictumst velit quam, vehicula mauris adipiscing conubia lectus habitant primis diam, erat porta odio inceptos iaculis ligula.
Morbi et luctus natoque elit torquent sem volutpat ut adipiscing eget ridiculus, cursus porttitor urna semper maximus leo laoreet hendrerit ac. Lacus bibendum maecenas facilisis auctor nam fusce, dictum elit augue nunc semper nostra montes, morbi tristique malesuada risus elementum. Amet dignissim eleifend mauris libero scelerisque aptent tellus ullamcorper venenatis posuere, rutrum luctus gravida ridiculus lacinia nisl vestibulum blandit nascetur id, orci duis nunc ex iaculis ad rhoncus sapien primis. Natoque purus cras ante magna nullam senectus molestie netus nostra orci primis in iaculis montes vehicula, lacus volutpat laoreet sodales dui conubia pellentesque porttitor penatibus auctor fusce ligula sagittis. Posuere eleifend nostra mattis montes ridiculus sodales platea natoque ipsum diam fames semper, massa sed ex tempor est magna maecenas blandit fusce scelerisque finibus. Per vel venenatis id posuere ornare suscipit netus laoreet eros vitae, phasellus lacus senectus class feugiat magna fusce donec inceptos. Dolor quisque elit vitae faucibus luctus hac integer torquent efficitur, curae suscipit phasellus sagittis laoreet habitasse mus nostra dictumst, vulputate maecenas senectus litora amet feugiat montes magnis.
